title: Lessons learned from a highly-active CD22-specific chimeric antigen receptor.
abstract: CD22 is an attractive target for the development of immunotherapeutic approaches for the therapy of B-cell malignancies. In particular, an m971 antibody-derived, second generation chimeric antigen receptor (CAR) that targets CD22 holds significant therapeutic promise. The key aspect for the development of such a highly-active CAR was its ability to target a membrane-proximal epitope of CD22.
authors.affiliation: Pediatric Oncology Branch; National Cancer Institute; Center for Cancer Research; National Institutes of Health; Bethesda, MD USA.
authors.forename: Adrienne H
authors.initials: AH
authors.lastname: Long
authors.forename: Waleed M
authors.initials: WM
authors.lastname: Haso
authors.forename: Rimas J
authors.initials: RJ
authors.lastname: Orentas
keywords: ALL; CD22; adoptive immunotherapy; leukemia; retroviral vectors